Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
The Indiana Cancer Pain and Depression (INCPAD) trial Design of a telecare management intervention for cancer-related symptoms and baseline characteristics of study participants.
OBJECTIVE Pain and depression are two of the most prevalent and treatable cancer-related symptoms , each present in at least 20 - 30 % of oncology patients . Both symptoms are frequently either unrecognized or undertreated , however . This article describes a telecare management intervention delivered by a nurse-psychiatrist team that is design ed to improve recognition and treatment of pain and depression . The enrolled sample is also described . METHODS The Indiana Cancer Pain and Depression study is a National Cancer Institute-sponsored r and omized clinical trial . Four hundred five patients with cancer-related pain and /or clinical ly significant depression from 16 urban or rural oncology practice s throughout Indiana have been enrolled and r and omized to either the  intervention group or to a  usual-care control group  . Intervention patients receive central ized telecare management coupled with automated home-based symptom monitoring . Outcomes will be assessed at 1 , 3 , 6 and 12 months by research assistants blinded to treatment arms . RESULTS Of 4465 patients screened , 2185 ( 49 % ) endorsed symptoms of  pain or depression . Of screen-positive patients , about one-third were ineligible ( most commonly due to pain or depression not meeting severity thresholds or to pain that is not related to cancer ) . Of the 405 patients enrolled , 32 % have depression only , 24 % have pain  only and 44 % have both depression and pain . At baseline , participants reported an average of 16.8 days out of the past 4 weeks during which they were confined to bed or had to reduce their usual activities by > or = 50 % due to pain or depression . Also , 176 ( 44 % ) reported being unable to work due to health reasons . CONCLUSIONS When completed , the Indiana Cancer Pain and Depression trial will test whether central ized telecare management coupled with automated home-based symptom monitoring improves outcomes in cancer patients with depression and /or pain . Findings will be important for both oncologists and mental health clinicians confronted with oncology patients ' depression or pain
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .